Danopharm Private Limited, a active private limited company, was established on 15 January 2009 in Mumbai, Maharashtra, India. Engaging in api manufacturers within the manufacturing sector, it holds CIN: U24100MH2009PTC189592. Registered under ROC Roc Mumbai. it is unlisted. It has an authorized capital of ₹2.00 Cr and a paid-up capital of ₹2.00 Cr.
Formerly known as Danopharm Chemicals Limited, Danopharm Private Limited. It upholds a compliant status. Employing 85 professional, Its leadership includes Jayanta Badalchandra Das (Director), Kamlesh Badal Das (Director), Satish Prabhakar Nachane (Director). Past directors included Satish Prabhakar Nachane, Mehul Satish Nachane. It holds ₹21.18 Cr open charges and ₹11.25 Cr settled loans. Its latest AGM occurred on 30 September 2024, with the balance sheet filed on 31 March 2024. It is based at Unit No 117, Ravi Kiran, 1St Floor, Near Monginis, Off New Link Road, Andheri(West), Mumbai, Maharashtra, 400053.
U24100MH2009PTC189592
189592
15 January 2009
₹2.00 Cr
₹2.00 Cr
Roc Mumbai
Unlisted
Active
Explore comprehensive insights into Danopharm Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Jayanta Badalchandra Das | Director | 15 Jan 2009 | Current |
| Kamlesh Badal Das | Director | 15 Jan 2009 | Current |
| Satish Prabhakar Nachane | Director | 03 Sep 2009 | Current |
| Ramesh Eknath Jadhav | Director | 16 Mar 2010 | Current |
| Sabu Daniel | Director | 16 Mar 2010 | Current |
| Kashinath Badal Das | Director | 15 Jan 2009 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Additional Director | 31 Jul 2010 | Past |
| Pramod Abcsdd | Additional Director | 31 Jul 2010 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Danopharm Chemicals Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 5.67% increase. The company also saw a substantial fall in profitability, with a 36.83% decrease in profit. The company's net worth Soared by an impressive increase of 16.26%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, Danopharm had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹211,800,000.00
₹112,500,000.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 21 Jul 2011 | State Bank Of India | ₹21.18 Cr | Open |
| 15 Sep 2009 | United Bank Of India | ₹11.25 Cr | Satisfied |
Explore comprehensive loan charge details -
Danopharm has a workforce of 85 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Danopharm, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Danopharm's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
The activity Danopharm Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records. was completed.
The activity Danopharm Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Mumbai. was completed.
A charge with State Bank Of India of Rs. 21.18 Cr registered on 21 Jul 2011 with Charge ID 10302455 was modified on 03 Aug 2023. was recorded as a recent event.
The activity A charge registered on 15 Sep 2009 via Charge ID 10177240 with United Bank Of India was fully satisfied on 15 Jun 2012. was completed.
Progress on A charge with State Bank Of India amounted to Rs. 21.18 Cr with Charge ID 10302455 was registered on 21 Jul 2011. was documented.
A charge with United Bank Of India of Rs. 11.25 Cr registered on 15 Sep 2009 with Charge ID 10177240 was modified on 23 Sep 2010. was recorded as a recent event.
The CIN of Danopharm Private Limited is U24100MH2009PTC189592.
Danopharm Private Limited is headquartered at Unit No 117, Ravi Kiran, 1St Floor, Near Monginis, Off New Link Road, Andheri(West), Mumbai, Maharashtra, 400053.
Danopharm Private Limited was incorporated on 15 January 2009.
The current directors of Danopharm Private Limited are
The primary industry of Danopharm Private Limited is Manufacturing.
Danopharm Private Limited is unlisted.
The authorized capital of Danopharm Private Limited is ₹2.00 Cr, and the paid-up capital is ₹2.00 Cr.
The compliance status of Danopharm Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX